about
Does milk intake promote prostate cancer initiation or progression via effects on insulin-like growth factors (IGFs)? A systematic review and meta-analysisAberrant anaplastic lymphoma kinase activity induces a p53 and Rb-dependent senescence-like arrest in the absence of detectable p53 stabilizationIdentification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK)+ and ALK- anaplastic large-cell lymphoma.Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOSOncogenic role of miR-155 in anaplastic large cell lymphoma lacking the t(2;5) translocation.What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?Fusion tyrosine kinase mediated signalling pathways in the transformation of haematopoietic cells.Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress.Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK.Jailbreak: oncogene-induced senescence and its evasion.Anaplastic large cell lymphoma (ALCL) and breast implants: breaking down the evidence.Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis.Twenty years of modelling NPM-ALK-induced lymphomagenesis.Breast implant associated anaplastic large cell lymphoma: The UK experience. Recommendations on its management and implications for informed consent.STAT3 regulated ARF expression suppresses prostate cancer metastasis.Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin.Malignant transformation of CD4+ T lymphocytes mediated by oncogenic kinase NPM/ALK recapitulates IL-2-induced cell signaling and gene expression reprogrammingPDGFR blockade is a rational and effective therapy for NPM-ALK-driven lymphomas.Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants.The lymphoma-associated fusion tyrosine kinase ITK-SYK requires pleckstrin homology domain-mediated membrane localization for activation and cellular transformation.The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms.Challenging perspectives on the cellular origins of lymphoma.Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase.When the guardian sleeps: Reactivation of the p53 pathway in cancer.Stem cell hunt in NHL.Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency.The male rat carcinogens limonene and sodium saccharin are not mutagenic to male Big Blue rats.Assays to predict the genotoxicity of the chromosomal mutagen etoposide -- focussing on the best assay.Inimitable Imatinib: the range of targeted tumours expands to include T-cell lymphoma.Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling.Developing the WCRF International/University of Bristol Methodology for Identifying and Carrying Out Systematic Reviews of Mechanisms of Exposure-Cancer Associations.Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27-28 June 2011.NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner.ALK in Neuroblastoma: Biological and Therapeutic Implications.The Role of Activator Protein-1 (AP-1) Family Members in CD30-Positive Lymphomas.Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.New avenues for targeted therapies and biomarkers in anaplastic large cell lymphoma.The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway.Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: a Children's Cancer and Leukaemia Group Study.ID: 263
P50
Q30235013-C0F3E70F-4511-4E61-BE17-1633FC92C126Q33851681-64AE2974-9FA0-499B-971D-2EA58F84CD4AQ34136298-1216877A-CC47-4284-BBB7-EB8CAA8476C1Q35220408-85E67555-333F-478E-84ED-0106A59E6572Q36018118-DA682A4F-568C-4D7D-9DB1-5EAA7BBB4A8BQ36132014-956ED282-42E6-4224-91D8-FBF1C28B3B87Q36398134-3578F59F-4B23-495D-BF55-6260C20B047EQ36511310-C65CDA77-C414-4AC4-8BA1-5548840010E1Q37133621-69E383C8-C818-40D0-97E3-B92ABDBF0C55Q37773037-45E26037-A5C5-4309-BF88-85195690E02CQ38283178-C88D9B7A-235C-4B1C-8B30-B01506E7327CQ38303954-02308BC3-3016-4F70-B7B2-50AF4CD28B36Q38472202-2DD757AA-99A8-449D-A5B6-F0E633DD7DE7Q38735573-25DE68D7-DFF7-4F50-A270-8FDF5D724F90Q38850627-AE97D8DA-69F7-420B-8FBF-C2B88D4EEF49Q38996543-E588415A-B88F-42C1-AAA7-81FA0D9F72DDQ39064213-77975B21-DC64-401B-AAED-A9A942875E64Q39259618-374305D3-8957-4D44-929D-DE3ADD42D816Q39442482-5E6B31B6-309D-43CB-AB1C-05A5C5A4F9E8Q39836717-7D678DAD-12D7-4A73-9784-D9B5E505F05AQ40207635-57B8B91D-4151-4E67-8522-DED40E83A0B3Q40523569-AAC1B5A9-89F4-4EE0-AAC5-6AAC5D2E4E2EQ40621401-B3FCFA24-5F00-4666-8C3B-EC4520B0A712Q41996415-62184DFE-DE4B-46EC-9452-A53FB2E8C244Q42122167-DFD17E76-709C-4624-AFCE-E2A5F99CBD46Q42199612-FA6526D2-D678-4DAE-8B21-2A88F285E1CBQ43649208-4560B35B-D82E-4352-AEA1-144AAFF8FBA0Q43715475-C9A1C8BF-3BC8-4509-9CA0-859C25B9B0C3Q45729167-ACD2FBAF-BAA2-4A0A-905D-EE6A689FD8AAQ46530451-AF4101DB-0DC4-4DC4-8075-0D5DD153E952Q47251840-F7B38E87-0430-448E-8885-B5702FDCEE6AQ51174486-1B1BFB51-56EC-45B0-B282-48CDE819E8EDQ51768651-BE4FA949-388A-4478-8A2C-FC3DE9A91B61Q52324760-C18B716B-C992-4316-AF50-8385784EE9D7Q52337767-A02F928F-D169-4CE4-A9E5-7BAA191BCB56Q52619047-D96FB090-3A06-4F78-AD24-244BFDBC204CQ52801642-8CDA187E-E5F7-46EB-B1E2-E8B5C9C68239Q53251955-9CFA382E-51B8-467E-9B64-48F9AD0F5AE1Q53376981-C0891C6E-4388-4EC1-97AB-4E6D84509B40Q57054600-87B80C33-2F0C-471B-BCB5-AB3E90220452
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Suzanne D Turner
@ast
Suzanne D Turner
@en
Suzanne D Turner
@es
Suzanne D Turner
@nl
Suzanne D Turner
@sl
type
label
Suzanne D Turner
@ast
Suzanne D Turner
@en
Suzanne D Turner
@es
Suzanne D Turner
@nl
Suzanne D Turner
@sl
altLabel
Suzanne D. Turner
@en
prefLabel
Suzanne D Turner
@ast
Suzanne D Turner
@en
Suzanne D Turner
@es
Suzanne D Turner
@nl
Suzanne D Turner
@sl
P1053
K-4405-2013
P106
P21
P2798
P31
P3829
P3835
suzanne-turner2
P496
0000-0002-8439-4507